Zynerba Pharmaceuticals Inc
F:6ZY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Z
|
Zynerba Pharmaceuticals Inc
F:6ZY
|
US |
|
N
|
NNIT A/S
F:5NN
|
DK |
|
Y
|
Yinson Holdings Bhd
KLSE:YINSON
|
MY |
|
Itochu Enex Co Ltd
TSE:8133
|
JP |
|
A
|
Altisource Asset Management Corp
AMEX:AAMC
|
VI |
|
G
|
Grupo Media Capital SGPS SA
ELI:MCP
|
PT |
Zynerba Pharmaceuticals Inc
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. The company is headquartered in Devon, Pennsylvania and currently employs 28 full-time employees. The company went IPO on 2015-08-05. Cannabinoids are a class of compounds derived from Cannabis plants. Its two primary cannabinoids contained in cannabis are cannabidiol and tetrahydrocannabinol (THC). The firm is developing Zygel, the pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of THC. Zygel is being developed as a clear gel with once- or twice-daily dosing and is targeting the treatment of behavioral symptoms of FXS, ASD and 22q. The company has evaluated Zygel targeting the reduction of seizures in patients with a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. The company is headquartered in Devon, Pennsylvania and currently employs 28 full-time employees. The company went IPO on 2015-08-05. Cannabinoids are a class of compounds derived from Cannabis plants. Its two primary cannabinoids contained in cannabis are cannabidiol and tetrahydrocannabinol (THC). The firm is developing Zygel, the pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of THC. Zygel is being developed as a clear gel with once- or twice-daily dosing and is targeting the treatment of behavioral symptoms of FXS, ASD and 22q. The company has evaluated Zygel targeting the reduction of seizures in patients with a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
